130 related articles for article (PubMed ID: 34202275)
1. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
Gurruchaga Sotés I; Alves AN; Arregui SV; Santander Lobera C
Curr Oncol; 2021 Jun; 28(4):2346-2350. PubMed ID: 34202275
[TBL] [Abstract][Full Text] [Related]
2. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
Park I; Shim YS; Go H; Hong BS; Lee JL
BMC Urol; 2019 Jun; 19(1):51. PubMed ID: 31182090
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
4. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
[No Abstract] [Full Text] [Related]
6. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
9. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
Soleimani M; Nappi L; Kollmannsberger C
Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
[TBL] [Abstract][Full Text] [Related]
10. Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
Wood LS; Ornstein MC
JCO Oncol Pract; 2020 Feb; 16(2_suppl):15s-19s. PubMed ID: 32045538
[TBL] [Abstract][Full Text] [Related]
11. Complete Pathologic Response to Pembrolizumab and Axitinib in a Patient With Sarcomatoid RCC and Ocrelizumab-Treated Multiple Sclerosis.
Neuzil K; Gessner K; Hedgepeth J; Wobker SE; Wallen EM; Morgan KP; Bjurlin MA; Rose TL
Urology; 2022 Jun; 164():50-54. PubMed ID: 34973243
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
13. Axitinib-ICIs boost the RCC armamentarium.
Romero D
Nat Rev Clin Oncol; 2019 Apr; 16(4):207. PubMed ID: 30833679
[No Abstract] [Full Text] [Related]
14. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
16. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
17. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
Rexer H; Bedke J
Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
[No Abstract] [Full Text] [Related]
18. Pembrolizumab + axitinib beyond first-line therapy for mRCC.
Thomas T
Nat Rev Urol; 2023 Mar; 20(3):131. PubMed ID: 36797430
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
20. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.
Leslie I; Boos LA; Larkin J; Pickering L
Expert Rev Anticancer Ther; 2020 May; 20(5):343-354. PubMed ID: 32293937
[No Abstract] [Full Text] [Related]
[Next] [New Search]